The double-edged sword of COX-2 selective NSAIDs

Area of Science:

• Pharmacology
• Clinical Therapeutics
• Drug Safety

Background:

• The development of cyclooxygenase-2 (COX-2) selective NSAIDs was predicated on reducing gastrointestinal adverse effects associated with nonselective NSAIDs.
• The hypotheses underlying COX-2 selective NSAID development—that gastrointestinal issues are the primary NSAID limitation and that COX-2 selectivity mitigates these—remain unproven.

Purpose of the Study:

• To critically evaluate the safety profile of COX-2 selective NSAIDs in comparison to nonselective NSAIDs.
• To examine the evidence supporting the initial hypotheses regarding COX-2 selective NSAID efficacy and safety.

Main Methods:

• Review of existing literature, including major clinical trials such as the Celecoxib Long-term Arthritis Safety Study (CLASS) and Vioxx Gastrointestinal Outcomes Research (VIGOR).
• Analysis of reported serious adverse events, focusing on gastrointestinal and non-gastrointestinal outcomes.

Main Results:

• Both CLASS and VIGOR studies indicated an increased incidence of total and non-gastrointestinal serious adverse events with COX-2 selective NSAIDs compared to nonselective NSAIDs.
• The observed increase in morbidity with COX-2 selective NSAIDs may be linked to drug selectivity or supramaximal dosing in trials.

Conclusions:

• The safety and efficacy of COX-2 selective NSAIDs compared to nonselective NSAIDs remain uncertain.
• Further randomized controlled trials are necessary to definitively assess whether COX-2 selective NSAIDs at usual doses offer improved gastrointestinal safety without increasing other serious adverse events.